| Co-Investigator(Kenkyū-buntansha) |
SHIMAZU Takeshi 大阪大学, 大学院医学系研究科, 教授 (50196474)
KUWAGATA Yasuyuki 大阪大学, 大学院医学系研究科, 招へい教授 (50273678)
SHIOZAKI Tadahiko 大阪大学, 大学院医学系研究科, 助教 (60278687)
OGURA Hiroshi 大阪大学, 大学院医学系研究科, 准教授 (70301265)
TASAKI Osamu 長崎大学, 大学病院, 教授 (90346221)
|
|---|
| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2013: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
|
|---|
| Research Abstract |
The intravenous cell transplantation using bone marrow stromal cells or bone marrow-derived mononuclear cells suppressed systemic inflammatory response, reduced multiple organ injuries and improved mortality rate against the animal model of critical illness. Sepsis induced in rodents altered the expression of gene to regulate stem cell function in the each organ. When endothelial cells or choroid plexus epithelial cells were co-cultured with bone marrow stromal cells, the factors to enhance stem cell function were up-regulated at the transcriptional level in their cells. Cell transplantation therapy is a promising modality to activate endogenous stem cells and to protect and regenerate injured organs in the treatment of critical illness.
|
